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Abstract 
Purpose: To investigate the effect of various solvent systems and gamma irradiation on the in vitro and 
in vivo performance of granisetron HCl injectable phase-sensitive in situ forming implants (ISFIs). 
Methods: ISFIs were prepared by mixing and sterilized by gamma irradiation. Effect of solvent system 
was studied. Injectability, polymer degradation and stability studies (4 and 25 oC for 4 months), viscosity 
measurements, as well as in vitro and in vivo (in rabbits) drug release, and also histological 
examinations for biocompatibility studies (in rabbits and rats) were carried out. 
Results: ISFIs showed good injectability from 20-gauge needle and their in vitro drug release increased 
in the following rank order of solvent/solvent combinations: dimethylsulphoxide (DMSO) > 
DMSO:prophylenecarbonate (PC) > DMSO:triacetin(TA) > DMSO:benzylbenzoate (BB). DMSO:PC 
incorporating ISFI gave zero order (r2 = 0.9503) drug release for 21 days; application of gamma 
irradiation accelerated drug release with a difference factor (f1) of 53 but zero order release (r2 = 9690) 
was maintained. Following test results for DMSO:PC including ISFI as decrease in molecular weight of 
polymer was descriptive for drug release behavior and sterilization effect, additionally dynamic 
viscosities decreased in line with polymer degradation and all forms of this ISFI showed plastic flow 
(fresh, irradiated, aged at 4 and 25 oC for 4 months). In vivo performance showed steady state plasma 
drug concentrations between 2 to 21 days with value of 0.55 ± 0.03 µg/ml and biocompatibility was 
confirmed by histological results obtained at specific stages of tissue reactions, and also by lack of 
fibrous capsule formation. 
Conclusion: An ISFI for long-term antiemetic therapy achieved in this preliminary study is promising 
and, therefore, further investigations are required. 
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The development of injectable ISFIs based on 
biodegradable phase-sensitive polymer solutions 
has received considerable attention in recent 
years due to advantages in manufacturing process 
and administration and avoidance of surgical 
intervention, thus improving patient compliance 
[1,2]. Formulation parameters for ISFIs such as 
amount and properties of drug, polymer and 
solvent are all active areas of research, and  
although delivery of high molecular weight (Mw) 
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therapeutics widely investigated, little research has 
been conducted to optimize ISFIs design for 
delivery of low Mw drugs [1-3].  
 
Problems such as poor in vitro–in vivo 
correlations, potential solvent toxicity and the 
possibility of initial burst effect leading to poor 
loading of drug may cause local or systemic side 
effects. Drawbacks associated with this system are 
still under investigation [1-3]. In the case of 
sterilization of ISFIs, the most preferable 
sterilization method is gamma irradiation which 
characteristically highly with a low dose rate 
(kGy/hour) [4]. Biocompatibility of ISFI systems is 
of utmost importance for clinical application. A 
desirable response of an implanted system shows 
a short-lived inflammatory response with a 
minimum of fibrosis resulting from the normal 
healing response of wounds [5].  
 
Granisetron HCl is a highly water soluble low Mw 
drug which is effective and well-tolerated in the 
management of chemotherapy-induced nausea 
and vomiting. In this study, the effect of various 
solvent systems and gamma irradiation on the in 
vitro performance of granisetron HCl ISFIs was 
investigated with regard to release behavior, 






The materials used include granisetron HCl (Cipla 
Limited, India); poly(D,L-lactide-co-glycolide 
(Resomer RG 504H, Boehringer Ingelheim GmbH, 
Ingelheim, Germany); ketamine hydrochloride 
(Ketalar, Pfizer, Turkey); dimethylsulphoxide, 
disodium hydrogenphosphate, potassium 
dihydrogenphosphate, sodium chloride, N-(1-
naphthyl) ethylenediamine dihydrochloride, 
acetonitrile, sodium hydroxide, sodium dihydrogen 
phosphate, toluene, ortho-phosphoric acid, 
formaldehyde (Merck, Darmstadt, Germany); 
propylene carbonate, tetrahydrofuran (Sigma-
Aldrich, Steinheim, Germany); triacetin, benzyl 
benzoate (Sigma, Germany), polystyrene analitical 
standard (Fluka,UK). All other chemicals were 
analytical grade. 
 
Preparation of ISFIs 
 
ISFIs (470 mg) were prepared by mixing PLGA (32 
%w/w) and solvent or mixture (1:1) of two solvents 
(64 %w/w) - DMSO or DMSO:BB, DMSO:TA, 
DMSO:PC) in glass vials until formation of a clear 
solution; granisetron HCl 4 %w/w was added and 
homogenized (Bandelin Sanoplus HD 2070, 
Germany). Liquid implant formulations coded with 
incorporating solvent and FD containing DMSO, 
FDB containing DMSO:BB, FDT containg 
DMSO:TA and FDP containig DMSO:PC  were 
then sealed and heated to 65 oC in a water bath to 




ISFI (FDP) in the sealed vials were irradiated with 
a 60Co source (Tenex Issledovatel, TAEK, Ankara, 
Turkey) and coded as RDP. A 25 kGy dose was 
applied following the European Pharmacopoeia 




Injectability of ISFIs, coded as FD, FDB, FDT, FDP 
and RDP, from 20-gauge needle attached to a 2 
ml injector and with an application of 20 psi force 
was determined. 
 
In vitro drug release studies 
 
ISFIs (470 mg) were injected into 10 ml phosphate 
buffer saline pH 7.4 containing vials and in vitro 
dissolution test carried out in a shaker bath (GFL 
1086, Germany) at horizontal strokes of 30/min 
and 37 oC (n = 3). Replenished, filtered (0.22 μm 
cellulose acetate membrane, Sartorius, Germany) 
and collected dissolution media at predetermined 
time points (1st, 4th, 24th hour and once on each of 
days 2 to 21) were analyzed using a UV 
spectrophotometer (Shimadzu 1240, Japan) at 
301 nm. The mechanism of drug release was 
analyzed kinetically by zero order, first order, 
Higuchi and Korsmeyer-Peppas models. 
Comparison of drug release profiles were 
evaluated by dissolution f1 and f2 parameters [8]. 
 
Polymer molecular weight studies 
 
Polymer degradation in ISFIs was investigated by 
gel permeation chromatography (GPC) (Agilent 
1100 HPLC System GPC/RID, Tübitak Atal, 
Ankara, Turkey) to determine the weight average 
polymer (Mw). In this determination, ISFIs (fresh, 
irradiated, taken out during dissolution test and 
irradiated form stored at 4 and 25 oC for 4 months) 
were dissolved in tetrahydrofuran (0.5 %w/v) and 
analysed with polystyrene standards (580 - 
370000 Da). Polydispersity index (PDI) of either 





Dynamic flow properties of liquid ISFIs (fresh, 
irradiated and irradiated form stored at 4 and 
25oC for 4 months) were measured (n = 3) by 
using rotation type programmable viscometer 
(Brookfield Engineering Laboratories Inc., Model 
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DV-2, USA) at 24 ± 0.1 °C with spindle TF no: 
96. The shear rate ranged from 10 to 200 s−1 
corresponding to 5 to 100 rpm with 10 s between 
each two successive speeds and then 
determined also in a descending order. 
Equilibration of the sample was for 5 min 
following loading of the viscometer. Ramp time 
for each viscosity step was 20 s. Data were 




Ethical approval was obtained for the animal 
studies from Ankara University Animal Welfare and 
Ethics Committee, Turkey (approval no. 2006/29). 
The animals (New Zealand rabbits, Wistar rats)  
were treated according to the principles of the care 
and use of laboratory animals [9]. 
 
In vivo drug release studies 
 
Following sedation with intramuscular 15 mg/kg 
ketamine hydrochloride, adult male New Zealand 
rabbits (weighing 3.0 - 3.5 kg, n = 4) were given a 
single subcutaneous injection of ISFI (470 mg) at 
their signed dorsal region using a 20-gauge needle 
and polypropylene rod shaped plungers injector. 
One rabbit was used as control. Blood (1 ml) 
obtained from the dorsal ear vein of the rabbits 
was collected into Lithium-heparin tubes and 
separated by centrifugation (Nüvefuge CN180) at 
3000 g for 3 min to obtain plasma on the 1st and 4th 
hours, and also on 1 st, 2 nd, 3 rd, 4 th, 7 th, 10 th, 14 th, 
18 th, 21 st days). The plasma samples were frozen 
at - 45 oC until high pressure liquid chromato-
graphy (HPLC, Shimadzu LC-10AD, Japan) 
analysis was carried out to determining drug 
concentration using the method of Pinguet et al 
[14]. The column used was SGE SS Wakosil II 
C18 RS (250 x 4.6 mm) with a mobile phase 
consisting of acetonitrile:buffer (adjusted to pH 4.5 
with 0.1M NaH2PO4 and o-phosphoric acid) in a 
ratio of 15:85 at a flow rate of 1 ml/min. Detection 
was carried out at λex of 305 nm and λem of 365 
nm. The developed method was evaluated for 
various system suitability parameters and 
validated for linearity, accuracy, precision, limit of 





Biocompatibility studies were accomplished in two 
parts. In the first part, rabbits that received ISFI fin 
the in vivo drug release studies were euthanized 
after final blood sampling on the 21st day. In the 
second part, ISFI was injected to dorsal signed 
region of six adult male Wistar rats (weighing 250 - 
350 g) to evaluate biocompatibility in terms of 
specific stages of tissue reactions. Two rats were 
used as control. For observation of tissue 
reactions on the 1st, 3rd and 21st days (following 
injection), a pair of rats was euthanized 
(intraperitoneal overdose ketamine hydrochloride) 
on each of these days. Tissue sampling and 
microscope analysis were the same for the rabbits 
and rats, and it was carried out by removing tissue 
samples from the injection sites using a scalpel, 
fixed by immersion in 10 % buffered formalin 
solution and then embedded in paraffin. 
Transverse sections (5 - 6 m) were cut using a 
microtome. Slides of the tissue sections were 
prepared and stained with hematoxylin and eosin. 
The slides were observed under the light 





The results were expressed as mean ± standard 
deviation. Statistical comparison was made using 
one-way ANOVA and p < 0.05 was considered 
statistically significant. Correlation analysis was 
performed by least square linear regression 
method and correlation coefficient examined for 
significance by Student’s t-test using GraphPad 
Instat 3.0 software. Statistical analyses were 
conducted using SSPS software version 9.0 for 




All ISFIs showed good injectability into 
phosphate buffer saline. Drug release profiles 
are presented in Figure 1(a). DMSO caused 
burst release from FD. Solvent combinations 
prevented initial burst and provided slow and 
similar drug release until 300 h later from FDP, 
FDT and FDB. Comparison of drug release 
profiles of FDP and its irradiated form, RDP, are 
presented in Figure 1(b). Among kinetic models 
investigated for drug release mechanism from 
FDP and RDP, the highest r2 values (0.9503 and 
0.9690, respectively) were obtained for zero 
order kinetic model. Difference between FDP and 
RDP profiles (Figure 1(b)) was indicated by the 
difference factor, f1 = 53 and similarity factor, f2= 
33 which are outside the respective ranges of f1 = 
0 - 15 and f2 = 50 - 100 [8] meaning that 
irradiation altered drug release. 
 
Determined Mw and PDI values of either plain 
PLGA or PLGA in various ISFI forms (fresh, 
irradiated and irradiated form aged at 4 and 25 
oC for 4 months) showed that Mw of PLGA was 
decreased by preparation, irradiation and ageing 
processes (Table 1). Decrease in polymer Mw in 
RDP was kinetically analyzed and degradation 
kinetics of polymer best fitted to first order kinetic  
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Figure 1:  Dissolution profiles of (a) FD(◊), FDP(□), FDT(∆), FDB(○) and (b) FDP(□), RDP(○) ISFIs. 
 
model (r2 = 0.9721 vs. Sy.x = 0.1016) with a 
degradation rate constantof (k) of 0,0030. The 
relationship between decrease in polymer Mw in 
RDP and increasing amount of released drug from 
RDP was investigated by correlation analysis and 
found significant (r2 = 0.9935). 
 
The dynamic viscosity of various forms of ISFI 
(fresh, irradiated and irradiated form aged at 4 and 
25 oC for 4 months) decreased compared to fresh 
form and all forms showed plastic flow behavior 
(Figure 2).  
 
Table 1: Molecular weight (Mw) and polydispersity index 
(PDI) of polymer alone, and in FDP, RDP and RDP 
during dissolution studies over 21 days and following 
storage at 4 and 25 oC for 4 months 
 







FDP 0 46880 2.297 

























RDP  4oC                  4 months 36172 2.370 
RDP  25oC               4 months 32998 2.465 
 
HPLC method was validated (r2 = 0.9998 for 
linearity and range, LOD=0.0354 μg and 
LOQ=0.107 μg) and used to determine drug 
concentration in plasma. The mean plasma profile 
of RDP in the rabbits (Figure 3) showed that 
following subcutaneous injection, mean drug 
plasma concentration was 1.2 µg/ml; it decreased 
to 0.54 µg/ml at the 48th hour and was steady at 
0.55 ± 0.03 µg/ml between 48 - 504 h; these were 
all greater than the value of LOQ.  
 
 
Figure 2: Rheograms of FDP (□), RDP(○) and RDP 
aged at 4oC (◊) and 25oC (∆) for 4 months. 
 
 
Figure 3:  Mean plasma drug profile of rabbits that 
received RDP formulation (n = 4).  
 
Tissue samples of rats and rabbits that received 
RDP were similar in terms of microscopical 
transformations on the 21st day as seen in Figure 
4(d) and (e) respectively. Histological sections 
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Figure 4:  Light photomicrographs of rat tissue sections (a) control group rat received normal saline (NS) on 1st 
day, (HE, x40), (b) 1st day; distinctive edema with congested vessels (black filled arrow) and neutrophile leucocytes 
(black hollow arrow) observed around the pale basophilic material (M) in subcutaneous tissue (HE, x100), (c) 3rd 
day; there is not any congested vessel observed around the basophilic material (M), however lymphocytes and 
histiocytes (black filled arrow) as well as neutrophile leucocytes (black hollow arrow) observed in subcutaneous 
tissue, (HE, x400),  (d) 21st day; histiocytes (black filled arrow) and multinuclear giant cells (black hollow arrow) 
stated around the degenerating material (M) in subcutaneous tissue, (HE, x200) and (e) rabbit tissue section 
obtained on 21st day; histiocytes (black filled arrow) and foreign type giant cells (black hollow arrow) stated around 
the degenerating material (M), (HE, x100) 
 
(c), (d) from the rats, and on evaluation in terms of 
specific stages of tissue reactions, acute 
inflammation on the 1st day and chronic 
inflammation on the 3rd and 21st days were 




Low melting and high boiling points of the 
solvents [10] in ISFIs allowed them to be liquid at 
the temperatures of injection (24 oC) and 
dissolution (37 oC), and thus facilitated 
injectability and in situ precipitation. Additionally, 
solvent levelss in ISFIs were below toxicity limits 
for human which can be predicted by their values 
of LD50 [10]. The hydrophilicity of solvent systems 
would be expected to affect the in vitro drug 
release and increase release in the rank order 
DMSO:PC > DMSO:TA > DMSO:BB, FDP > FDT 
> FDB. Thus, FDP which incorporates DMSO:PC 
solvent system with higher hydrophilicity, showed 
better and regular release profile than the others. 
Irradiation of FDP to form RDP resulted in a 
significant increase in drug release.  
 
In the context of achieving sustained release of 
low Mw granisetron HCl from ISFIs for 21 days, 
the results show that solvent combination 
provided a balanced hydrophilicity and thus 
yielded the desired release profile. The irradiation 
effect on drug release can be attributed to 
decrease in Mw and Tg of polymer [11], and aided 
by the hydrophilic putative solvent system.  
 
During ISFI preparation process, application of 
sonication and heat probably caused a decrease 
in the Mw of PLGA; breaking of units from the 
chain ends of PLGA [12] peobably resulted in 
increase in its PDI value which is inferred from 
the results of studies that used magnetic stirring 
at room temperature [13] and extrusion at 75 oC 
[12] for the preparation of PLGA formulations. 
Application of gamma irradiation to ISFI caused a 
decrease in Mw of PLGA but not caused a 
significant change in its PDI value which 
supported by the study of Friess and Schlapp 
[14].  During dissolution, PLGA with acid end 
groups was assumed to have increased the 
hydrophilicity and ability of water uptake which 
results in an increase in PLGA degradation time 
[15]. 
  
The degradation mechanism of polymer, based 
on PDI data could be defined as degradation 
from the chain ends until the 4th day, random 
chain scissions between the 7th and 14th day and 
dominantly random chain scissions between the 
14th and 21st day. It could be inferred that due to 
random chain scissions, polymer was separated 
into short chains, increased its solubility which 
catalyzes hydrolysis and thus accelerated the 
release of hydrophilic drug [15]; this could be 
attributed to the fast release between 7th and 14th 
day. Chain scissions are formed in the interior of 
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an implant due to autocatalysis while chain 
scission coexists with breaking away of units 
from chain ends on the surface of implants [15]  
thus occurred in dominantly chain scissions 
between 14th and 21st days.  
 
Decrease in polymer Mw in RDP was kinetically 
best fitted to first order model and this is in 
agreement with the findings of Kenley et al [16] 
which investigated the decomposition kinetics of 
PLGA (50:50 lactide:glycolide copoymer). 
Polymer degradation data correlated with drug 
release behavior from RDP. Storage of RDP at 4 
and 25 oC for 4 months resulted in less decrease 
in Mw of PLGA probably due to slower molecular 
movement and partial phase separation of ISFI 
that originated from frozen DMSO (melting point 
+18.5 oC). The stability results do not agree with 
those of another study showed that phase 
sensitive ISFI systems were stable at 4 oC and 
acceptably stable at 25 oC for 300 days [17]. The 
decreased dynamic viscosities of different forms 
of ISFI (fresh, irradiated and irradiated form aged 
at 4oC and 25oC for 4 months) can be attributed 
to the decrease in the Mw of PLGA (Figure 2). 
   
In vivo performance of DMSO:PC incorporating 
ISFI in rabbits showed steady state plasma drug 
concentration between 2 and 21 days. Both in 
vitro and in vivo release showed agreement with 
regard to a burst effect and this is also supported 
by the findings of Kempe et al [18] about good. 
Biocompatibility results obtained from rabbits and 
rats were acceptable for RDP and there was no 
fibrous capsule formation around the 
degenerating material which could have 
decreased movement of the released drug from 
the implant to tissue. The resulting patterns 
around the implant material were defined as 
foreign body reaction [5,19] and the implant was 
considered biocompatible, a finding supported by 




The combination of hydrophilic and hydrophobic 
solvents may be useful to control the release of 
high water soluble low Mw drug from phase 
sensitive ISFI systems, and these systems are 
easy to prepare and apply up to a period of 3 
weeks. In vivo performance and biocompatibility 
data for this system are encouraging but further 
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